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Dabigatran in Patients With
Nonvalvular Atrial Fibrillation
In the “2011 ACCF/AHA/HRS Focused Update on the Manage-
ment of Patients With Atrial Fibrillation (Update on Dabigatran)”
(1), the writing committee provides a Class IB recommendation for
abigatran as a useful “alternative to warfarin” in most patients with
onvalvular atrial fibrillation.
The guideline, like the manufacturer’s prescribing information,
mplies that a patient with creatinine clearance 15 to 30 ml/min is a
andidate for dabigatran 75 mg twice daily (bid), despite the fact that
atients with creatinine clearance 30 ml/min were excluded from
he RE-LY trial (2), on which the recommendation is primarily
ased. We do not know, in fact, that dabigatran 75 mg bid is safe in
hese fragile patients or that it is effective in anyone.
How did the 75-mg dose come about? The U.S. Food and Drug
dministration (FDA) Division of Cardiovascular and Renal Prod-
cts explains, but hardly reassures: “Based on pharmacokinetic mod-
ling, comparing pharmacokinetic data from RE-LY with data from
small study of subjects with compromised renal function, a dosing
egimen of 75 mg bid appears appropriate for patients with estimated
rCL 15 to 30 mL/min” (3).
Although it is encouraging that intracranial hemorrhage was less
requent with dabigatran than with warfarin in RE-LY, most sea-
oned clinicians will recall any number of patients who presented with
verwhelming, fatal hemorrhagic diatheses, with or without intracra-
ial hemorrhage, as a result of over-anticoagulation. Compared with
arfarin, dabigatran has the advantage—and the disadvantage—of
ot being subject to periodic monitoring and titration; it is
liminated by an organ whose function routinely varies remarkably
n the elderly, and it has no antidote. As I contemplate using 150
g bid, effectively within a one-size-fits-all paradigm, my concern
s that we may begin to collect more such tragic vignettes.
The “average” patient in RE-LY was 71 years of age, weighed 83
g, and had a creatinine clearance (by the Cockcroft-Gault method)
f 106 ml/min. An 80-year-old woman who weighs 60 kg and has a
erum creatinine level of 1.3 has an estimated creatinine clearance of
3 ml/min. It is generally agreed that formulas for calculating
lomerular filtration rate are fraught with error, but assuming 33
l/min is correct, what dose of dabigatran is right for her? Here is the
DA’s advice: “Patients with CrCL31 mL/min should receive 150
g bid” (3).
It appears that we are to assume that this woman’s risk of serious
leeding with dabigatran 150 mg bid exceeds that of the more robust
average” patient only by a small, clinically acceptable margin, but, in
act, we do not know what that margin is.What is more, although sheualifies for 150 mg bid (according to the manufacturer, the FDA,
nd the new guideline) a week from now, when her serum creatinine
evel chances to be 1.5 and her creatinine clearance 28ml/min, she will
ot qualify. She will instead be relegated to an untested dose that
eemed “appropriate” on pharmacokinetic grounds.
In summary, the recommendation to use dabigatran 75 mg bid in
atients with atrial fibrillation is Class IIb at best, and Level C; there
s no randomized trial. The recommendation for 150 mg bid,
lthough Level B, is Class IIa: “additional studies with focused
bjectives are needed.” The nearly unqualified endorsement of Class I
tatus is not warranted.
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Reply
The American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is rigorous
and involves several layers of review by the writing committee, external
peer reviewers, and participating organizations in the document, it
cannot respond to each issue raised after a guideline has been
published. The information, however, is forwarded to the Writing
Committee Chair and Oversight Task Force for review. If any issue
is deemed by the ACCF/AHA to affect patient safety, it will be
considered immediately. Otherwise, the information will be consid-
ered during the next update or revision of the guideline.
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